Udayavni Special

Bharat Biotech planning to launch Covid-19 vaccine ‘Covaxin’ in second quarter of 2021


PTI, Nov 1, 2020, 1:39 PM IST

New Delhi: Bharat Biotech is planning to launch its vaccine for Covid-19 in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities, a top company official said.

It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.

The company’s vaccine candidate Covaxin has been developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV) using inactivated Sars-Cov-2, the virus that causes Covid-19. The virus was isolated in an ICMR lab.

“If we get all the approvals after establishing strong experimental evidence and data, and efficacy and safety data in our last stage of trials, we aim to launch the vaccine in Q2 of 2021,” Bharat Biotech International Executive Director Sai Prasad told PTI.

After the company received approval from the Drugs Controller General of India (DCGI) to conduct Phase 3 clinical trial to establish the efficacy of the vaccine candidate, it has begun site preparatory exercises for Phase 3, recruitment and dosage will begin in November, he added.

“The trial to be conducted in 25 to 30 sites across 13-14 states will provide two doses each for the vaccine and placebo recipients. About 2,000 subjects could be enrolled per hospital,” Prasad said.

Asked about the investment on the vaccine, he said: “Our investment is about Rs 350-400 crore for the development of vaccine and the new manufacturing facilities, which include our investments for conducting the Phase 3 clinical trial, in the next six months”.

On the company’s plan to sell the vaccine to the government or to private players, Prasad said: “We are looking to supply for both government and private markets. We are also in preliminary discussions with other countries for probable supply.”

Prasad said the price of the vaccine is yet to be determined, as the company is still looking at the cost of product development.

“Our immediate focus is to conduct Phase 3 trial successfully across sites,” he added.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

K’taka COVID-19 update: 1446 new cases, 894 discharges, 13 dead on Dec 2

Shivamogga: After attack on Bajrang Dal worker, situation remains tense; curfew imposed

Domestic flights allowed at 80% of pre-covid levels from today: Centre

NCB suspends 2 IOs for no show in court in Bharti Singh case

Ex-Punjab CM Parkash Singh Badal returns Padma award over farm laws

Kerala CM calls for high-level meeting to tackle rain fury

Criminal networks could try to sell fake COVID vaccines physically and on internet, warns Interpol



Related Articles More

K’taka COVID-19 update: 1446 new cases, 894 discharges, 13 dead on Dec 2

5 Covid-19 Vaccines Undergoing Trial in India Logistically Feasible for Distribution in Both Urban, Rural Areas: AIIMS Director

Committed to engaging with Indian govt to make vaccine available in country: Pfizer

Vaccine 1st puts spotlight on German pharma company BioNTech

K’taka COVID-19 update: 1440 new cases, 983 discharges, 16 deaths on Dec 1

MUST WATCH

Pro-terror graffiti case culprits will be arrested soon: Basavaraj Bommai

Meal of Bakasur : Hotel Fish Campus Udupi | Udayavani

Things You Should Know When Starting A Business | Profitable Business Ideas After Lockdown

Mangalore Boat tragedy: We’re with families of deceased, says Kota after announcing Rs 6 lakh compensation

Mangaluru boat tragedy: Body of another fisherman recovered

Latest Additions

K’taka COVID-19 update: 1446 new cases, 894 discharges, 13 dead on Dec 2

Azerbaijan discloses Nagorno-Karabakh conflict troop death toll

PM to lay foundation stones of 2 projects in Gujarat on Dec 15

Udupi Sri Krishna Matha installs Kannada nameboards after controversy

Hyderabad Civic Poll Results: Counting of Votes to Begin at 8 am Tomorrow

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.